Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | IP6K2 | Q9UHH9 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309884 | 0.88 | ADORA3 (0.49) | CSNK2A2CSNK2BCSNK2A1ALDH2HPGD | |
| SCHEMBL1312377 | 0.87 | CLK2 (0.39) | PTGESALDH2KMT2ACYP3A4HPGD | |
| SCHEMBL1310945 | 0.86 | ALPL (0.53) | CSNK2A2CSNK2BCSNK2A1KMT2ACYP3A4 | |
| SCHEMBL1312198 | 0.85 | AR (0.44) | MAPTMAOBARGABRPGABRD | |
| SCHEMBL1309569 | 0.85 | CYP3A4 (0.46) | PTGESKMT2ACYP3A4HPGDMAPT | |
| SCHEMBL1310998 | 0.85 | CYP3A4 (0.50) | PTGESCSNK2A2CSNK2BCSNK2A1KMT2A | |
| SCHEMBL1312794 | 0.84 | ALDH2 (0.38) | PTGESCSNK2A2CSNK2BCSNK2A1ALDH2 | |
| SCHEMBL1310047 | 0.83 | EGFR (0.53) | KMT2ACYP3A4HPGDMAPTSMN1; SMN2 | |
| SCHEMBL1311018 | 0.80 | ALDH2 (0.40) | CSNK2A2CSNK2BCSNK2A1ALDH2KMT2A | |
| SCHEMBL1309829 | 0.78 | MAPT (0.49) | CYP3A4HPGDMAPTTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275707-A1 | SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS | LEE KUO-HSIUNG | 2011-11-10 | — | — | US | disclosed |
| WO-2010080415-A2 | SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275707-A1 | SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS | TP53, FOLR1, THPO | PTGES 3614/4885CSNK2A2 1782/4885CSNK2B 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.